new_0222_0289|RXRX|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0289|RXRX|1|Recursion Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|Recursion Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|Recursion Pharmaceuticals Inc Inventories (Quarterly) (USD)|Recursion Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|Recursion Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|Recursion Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|Recursion Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|Recursion Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|Recursion Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|Recursion Pharmaceuticals Inc Book Value (Quarterly) (USD)|Recursion Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|Recursion Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|Recursion Pharmaceuticals Inc EV to Revenues|Recursion Pharmaceuticals Inc EV to Earnings|Recursion Pharmaceuticals Inc EV to Free Cash Flow|Recursion Pharmaceuticals Inc EV to Assets (Quarterly)|Recursion Pharmaceuticals Inc PS Ratio|Recursion Pharmaceuticals Inc PE Ratio|Recursion Pharmaceuticals Inc Price to Book Value|Recursion Pharmaceuticals Inc PEG Ratio|Recursion Pharmaceuticals Inc Debt to Equity Ratio|Recursion Pharmaceuticals Inc Dividend Yield|Recursion Pharmaceuticals Inc Shareholder Yield (TTM)|Recursion Pharmaceuticals Inc Percent of Shares Outstanding Short|Recursion Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|Recursion Pharmaceuticals Inc Total Payables (Quarterly) (USD)|Recursion Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|Recursion Pharmaceuticals Inc Return on Invested Capital|Recursion Pharmaceuticals Inc Quality Ratio Score|Recursion Pharmaceuticals Inc Momentum Score|Recursion Pharmaceuticals Inc Beta (1Y)|Recursion Pharmaceuticals Inc Sustainable Growth Rate (TTM)|Recursion Pharmaceuticals Inc Institutional Investor Ownership Percentage|Recursion Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|Recursion Pharmaceuticals Inc Total Employees (Annual)|Recursion Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|Recursion Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|Recursion Pharmaceuticals Inc Shares Outstanding|Recursion Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|Recursion Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|Recursion Pharmaceuticals Inc Payout Ratio|Recursion Pharmaceuticals Inc Quick Ratio (Quarterly)|Recursion Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|Recursion Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|Recursion Pharmaceuticals Inc Effective Tax Rate (TTM)|Recursion Pharmaceuticals Inc Return on Equity|Recursion Pharmaceuticals Inc Net Income (TTM) (USD)|Recursion Pharmaceuticals Inc Revenue (TTM) (USD)|Recursion Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|Recursion Pharmaceuticals Inc Revenue (Quarterly) (USD)|Recursion Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|Recursion Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|Recursion Pharmaceuticals Inc Net Income (Quarterly) (USD)|Recursion Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|Recursion Pharmaceuticals Inc Price (USD)|Recursion Pharmaceuticals Inc Total Return Price (USD)|Recursion Pharmaceuticals Inc Enterprise Value (USD)|Recursion Pharmaceuticals Inc 30-Day Average Daily Volume|Recursion Pharmaceuticals Inc 1 Year Price Returns (Daily)|Recursion Pharmaceuticals Inc Short Interest|Recursion Pharmaceuticals Inc PE Ratio (Forward)|Recursion Pharmaceuticals Inc PE Ratio (Forward 1y)|Recursion Pharmaceuticals Inc PS Ratio (Forward)|Recursion Pharmaceuticals Inc PS Ratio (Forward 1y)|Recursion Pharmaceuticals Inc Quarterly EPS Estimates (USD)|Recursion Pharmaceuticals Inc Quarterly Revenue Estimates (USD)|Recursion Pharmaceuticals Inc Quarterly EPS Surprise|Recursion Pharmaceuticals Inc Quarterly Revenue Surprise|Recursion Pharmaceuticals Inc Quarterly Actual EPS (USD)|Recursion Pharmaceuticals Inc Quarterly Actual Revenue (USD)|Recursion Pharmaceuticals Inc Revenue Estimates for Current Fiscal Year (USD)|Recursion Pharmaceuticals Inc Revenue Estimates for Next Fiscal Year (USD)|Recursion Pharmaceuticals Inc Price Target (USD)|Recursion Pharmaceuticals Inc Consensus Recommendation|Recursion Pharmaceuticals Inc Price Target Num Estimates|Recursion Pharmaceuticals Inc EPS Estimates for Current Fiscal Year (USD)|Recursion Pharmaceuticals Inc EPS Estimates for Next Fiscal Year (USD)|Recursion Pharmaceuticals Inc Research and Development Expense (Quarterly) (USD)|Recursion Pharmaceuticals Inc Reconciled Depreciation (Quarterly) (USD)|Recursion Pharmaceuticals Inc Non-Operating Interest Expense (Quarterly) (USD)|Recursion Pharmaceuticals Inc Land and Improvements (Quarterly) (USD)|Recursion Pharmaceuticals Inc Buildings and Improvements (Quarterly) (USD)|Recursion Pharmaceuticals Inc Other Properties (Quarterly) (USD)|Recursion Pharmaceuticals Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0289|RXRX|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0289|RXRX|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0289|RXRX|5|91|91||91|91|91|91|91||91|91||1.43925233645|92|1.43925233645|92|1.43925233645||1.43827160494||91|1.43925233645|92|15.3333333333|91|91|91|92||||92|30.6666666667|91.3333333333|33|91.3333333333|91.3333333333|25.25||91|91|91|91.3333333333|91.4||92|91|91||91.3333333333||91.3333333333|91.3333333333|91.3333333333|1.43925233645|1.43925233645|1.43925233645|1.44324324324||15.3333333333|||1.44117647059|1.44117647059|91.3333333333|91.4285714286|91.5|91.5|91.5|91.5|25.3|28.1111111111|31.3333333333|21.6923076923|31.3333333333|21.9090909091|23.3333333333|91.3333333333|91.3333333333|91.3333333333|||91|91||
new_0222_0289|RXRX|6|3|3||3|3|3|3|3||3|3||214|1|214|1|214||162||3|214|1|18|3|3|3|1||||1|9|6|1|6|6|8||3|3|3|6|5||1|3|3||6||6|6|6|214|214|214|185||18|||34|34|6|7|2|2|2|2|10|9|9|13|9|11|9|6|6|6|||3|3||
new_0222_0289|RXRX|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0289|RXRX|202003||||||||||||||||||||||||||||||||||112.4661||-0.1638|5.561||||||-0.1638|||||||0.06||-18.424|-18.424|-0.081||||||||||||||||||||||||12.842|0.937|0.301||||||
new_0222_0289|RXRX|202006||||||||||||||||||||||||||||||||||112.4661||-0.1684|5.159||||||-0.1656|||||||0.186||-18.943|-18.943|-0.402||||||||||||||||||||||||13.244|1.024|0.426||||||
new_0222_0289|RXRX|202009||||||||||||||||||||||||||||||||||112.4661||-0.2123|6.964||||||-0.203|||||||1.025||-23.873|-23.873|-0.355||||||||||||||||||||||||16.535|0.857|0.401||||||
new_0222_0289|RXRX|202012|269.478|262.126||25.967|2.49|504.874|23.099|481.775||-206.289|-213.601||||||||||-0.0605||||0.156|1.352||||||||112.4661|216|-0.2291|7.574|||155.9127||11.3547|-0.2334||||-87.006|3.962||2.691||-25.766|-25.766|-0.185||||||||||||||||||||||||20.698|1.624|0.231|||19.701|1.075||
new_0222_0289|RXRX|202103|221.822|214.088||44.642|2.414|504.974|26.854|478.12||-233.031|-244.318||838.5377||-64.6784||637.2441||||-0.0536|||0.9248|0.071|3.125|||||||16.0574|155.9127|218|-0.197|8.937|168.3207||155.9127||7.9749|-0.197||||-99.299|6.464||2.562||-30.717|-30.717|-0.233|33.4|33.4|5420.3074|490141.0667||1556547|||||-0.2322|2.7667|0.9645|-7.3977|-0.23|2.562|10.155|19.737|33.2|1.8|5|-1.1261|-1.3302|24.109|1.402|0.249|||21.234|18.994|26.36|
new_0222_0289|RXRX|202106|647.635|632.738||48.549|2.338|55.876|29.54|26.336||642.714|-287.719||626.1884|-44.6631|-51.9802|7.9122|536.7339||9.565||0.0195||-7.5707|2.8557|0.049|3.196|0.002|-154.1036||||-182.5378|33.6934|138.3606||-0.31|13.854|168.4259||168.4259||21.4214|-0.31|-462.901||-182.5378|-123.757|8.827||2.549||-43.401|-43.401|-2.472|36.5|36.5|5527.3654|486161.2667||4809774|||||-0.241|2.725|-28.62|-6.4587|-0.31|2.549|10.337|11.0333|32.4|1.8|5|-1.2789|-1.3868|29.624|2.331|2.501|||25.562|20.005|30.35|25.22
new_0222_0289|RXRX|202109|600.87|578.91||55.439|2.262|59.574|42.943|16.631||599.032|-335.147||319.4781|-22.4159|-25.636|5.0138|320.1681||6.4776||0.0012||-11.9334|7.1102|2.282|6.326|0.002|-70.0902||||-73.4333|41.1547|168.5335||-0.28|15.69|168.635||168.635||13.534|-0.2751|||-73.4333|-147.312|10.336||2.534||-47.428|-47.428|-0.17|23.01|23.01|3302.1254|564105.8||11990335|||||-0.2804|2.7|0.1533|-6.1481|-0.28|2.534|10.5028|11.025|33.1667|1.6667|6|-1.2516|-1.4175|33.246|2.436|0.22|||29.664|20.005|19.15|19.12
new_0222_0289|RXRX|202112|||||||||||||224.1376||-17.9856||238.352||4.8326|||||7.9299|||||||||47.1325||||||||||||||||||||||17.13|17.13|2316.6858|2149636.3333||13400928|||45.8124|67.8205|-0.3075|5.2|||||12.0005|63.1893|33.8333|1.6667|6|-1.1894|-1.1235||||||||11.84|10.2
new_0222_0289|RXRX|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.4|8.8||||||||||||||||||||
new_0222_0289|RXRX|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.43|8.8||||||||||||||||||||
new_0222_0289|RXRX|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.46|8.8||||||||||||||||||||
new_0222_0289|RXRX|202212||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||15.1||||||||||||||||||||